Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read, comprehend, and complete the informed consent form~* Male or female subjects, age 18-80 years,~* Suspected EoE or has a diagnoses of EoE with current active disease,~Exclusion Criteria:~* History of esophageal stricture precluding passage of the endoscope or sponge,~* Pregnancy, or planned pregnancy during the course of the study,~* Any history of esophageal varices, liver impairment of moderate or worse severity (Child's- Pugh class B \& C) or evidence of varices noted on any past endoscopy,~* Any history of esophageal surgery, except for uncomplicated fundoplication~* History of coagulopathy, with international normalized ratio (INR) \>1.3 and/or platelet count of \<75,000.~* Current use of blood thinners such as coumadin, warfarin, clopidogrel, heparin and/or low molecular weight heparin (requires discontinuation of medication 7 days prior to and 7 days after esophagogastroduodenoscopy (EGD) and Cytosponge administration, aspirin use is OK).~* Are allergic to local anesthetics such as lidocaine (these subjects may opt not to receive the optional lidocaine gargle prior to the Cytosponge administration and still be eligible).~* Have not fasted the night before administration of the Cytosponge.~* History of perforation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EoE Patients (Type: EXPERIMENTAL): Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).